Cargando…

Retrospective analysis to describe associations between tumor necrosis factor alpha inhibitors and COPD-related hospitalizations

BACKGROUND: Limited information exists on the impact of tumor necrosis factor inhibition on COPD exacerbations. This retrospective study characterized this impact among COPD patients with underlying autoimmune conditions, exposed to tumor necrosis factor inhibitors (TNFi) and/or non-biologic disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Accortt, Neil A, Chung, James B, Bonafede, Machaon, Limone, Brendan L, Mannino, David M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530069/ https://www.ncbi.nlm.nih.gov/pubmed/28790811 http://dx.doi.org/10.2147/COPD.S127815

Ejemplares similares

The burden of cystic fibrosis in the Medicaid population
por: Hassan, Mariam, et al.
Publicado: (2018)

Dose relationship between oral glucocorticoids and tumor necrosis factor inhibitors and the risk of hospitalized infectious events among patients with rheumatoid arthritis
por: Schenfeld, Jennifer, et al.
Publicado: (2017)

Treatment effectiveness and treatment patterns among rheumatoid arthritis patients after switching from a tumor necrosis factor inhibitor to another medication
por: Bonafede, Machaon MK, et al.
Publicado: (2016)

Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
por: Bonafede, Machaon, et al.
Publicado: (2014)

Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

Healthcare resource utilization and costs among children with cystic fibrosis in the United States
por: Thorat, Teja, et al.
Publicado: (2021)

A human inhibitor of tumor necrosis factor alpha
Publicado: (1988)

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis
por: Callejas-Rubio, José Luis, et al.
Publicado: (2008)

Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients
por: Tanni, Suzana E, et al.
Publicado: (2010)

Healthcare utilization and cost of cancer-related care prior to allogeneic hematopoietic cell transplantation for hematologic malignancies in the US: a retrospective real-world analysis
por: Bonafede, Machaon, et al.
Publicado: (2021)

Phytochemicals as inhibitors of tumor necrosis factor alpha and neuroinflammatory responses in neurodegenerative diseases
por: Zahedipour, Fatemeh, et al.
Publicado: (2022)

The adverse drug reactions to tumor necrosis factor alpha inhibitor
por: Park, Hye-Kyung, et al.
Publicado: (2014)

Tumor Necrosis Factor Alpha Inhibitor-Induced Acute Pancreatitis
por: Werlang, Monia E., et al.
Publicado: (2017)

Mechanisms of Tumor Necrosis Factor-Alpha Inhibitor-Induced Systemic Lupus Erythematosus
por: Yen, Chung-Yang, et al.
Publicado: (2022)

Are patients with high-risk polycythemia vera receiving cytoreductive medications? A retrospective analysis of real-world data
por: Paranagama, Dilan, et al.
Publicado: (2018)

Differences in health care outcomes between postdischarge COPD patients treated with inhaled corticosteroid/long-acting β(2)-agonist via dry-powder inhalers and pressurized metered-dose inhalers
por: Wittbrodt, Eric T, et al.
Publicado: (2018)

Tumor necrosis factor alpha inhibitors and demyelinating disease: what is behind it?
por: Kucharz, Eugeniusz Józef, et al.
Publicado: (2021)

Medication usage, treatment intensification, and medical cost in patients with type 2 diabetes: a retrospective database study
por: Bonafede, Machaon, et al.
Publicado: (2016)

Medication utilization patterns among type 2 diabetes patients initiating Exenatide BID or insulin glargine: a retrospective database study
por: Pawaskar, Manjiri, et al.
Publicado: (2013)

Comorbidities as a driver of the excess costs of community-acquired pneumonia in U.S. commercially-insured working age adults
por: Polsky, Daniel, et al.
Publicado: (2012)

Familial secondary hyperhidrosis associated with tumor necrosis factor–alpha inhibitor treatment
por: Ikediobi, Ogechi, et al.
Publicado: (2015)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US
por: Bonafede, Machaon M, et al.
Publicado: (2013)

Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
por: Johnson, Barbara H., et al.
Publicado: (2015)

Short- and longer-term health-care resource utilization and costs associated with acute ischemic stroke
por: Johnson, Barbara H, et al.
Publicado: (2016)

Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study
por: Kishimoto, Megumi, et al.
Publicado: (2023)

Appearance of ANCA – associated vasculitis under Tumor necrosis factor-alpha inhibitors treatment
por: Reitblat, Tatiana, et al.
Publicado: (2013)

Two Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors
por: Masukawa, Ena, et al.
Publicado: (2021)

The Utility of Frequent Laboratory Monitoring for Patients on Tumor Necrosis Factor-Alpha Inhibitors in Dermatology
por: Houpe, Jessica E., et al.
Publicado: (2022)

Tumor Necrosis Factor Alpha Signaling and Organogenesis
por: You, Kai, et al.
Publicado: (2021)

Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
por: Bonafede, Machaon, et al.
Publicado: (2020)

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis
por: Ma, Zeren, et al.
Publicado: (2017)

Severe lupus induced by the tumor necrosis factor-alpha inhibitor Anbainuo: a case report
por: Pan, Xiaoli, et al.
Publicado: (2021)

Tumor Necrosis Factor-Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis: A Systematic Review
por: Nair, Shaalina, et al.
Publicado: (2022)

Treatment Patterns During Major Depressive Episodes Among Patients with Major Depressive Disorder: A Retrospective Database Analysis
por: Jain, Rakesh, et al.
Publicado: (2022)

Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera
por: Parasuraman, Shreekant V., et al.
Publicado: (2018)

TUMOR NECROSIS FACTOR-ALPHA IN PATIENTS WITH ALOPECIA AREATA
por: Kasumagic-Halilovic, Emina, et al.
Publicado: (2011)

Glaucomatous neurodegeneration: An eye on tumor necrosis factor-alpha
por: Agarwal, Renu, et al.
Publicado: (2012)

Tumor Necrosis Factor Alpha: Implications of Anesthesia on Cancers
por: Tseng, Wei-Cheng, et al.
Publicado: (2023)

Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice
por: Rusman, Tamara, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e872svsh2967ngnjkfobv7542t